Oral Fosfomycin Effectively Clears E. coli UTIs
Yes, oral fosfomycin tromethamine is highly effective for clearing urinary tract infections caused by Escherichia coli, with clinical cure rates of 94-99% and microbiological eradication rates of 75-94% when used as a single 3-gram dose for uncomplicated cystitis in women. 1, 2, 3
FDA-Approved Indication and Mechanism
Fosfomycin tromethamine is FDA-approved specifically for treating uncomplicated UTIs (acute cystitis) in women caused by susceptible E. coli strains 2. The drug achieves bactericidal activity by irreversibly blocking bacterial cell wall synthesis through inactivation of enolpyruvyl transferase, and it reduces bacterial adherence to uroepithelial cells 2.
Clinical Efficacy Data
Standard E. coli Infections
- Single 3-gram dose achieves urinary concentrations of 706 mcg/mL within 2-4 hours, maintaining levels >100 mcg/mL for 26 hours 2
- Clinical trials demonstrate bacteriological eradication rates of 75-90% at 5-11 days post-treatment and 62-93% at 4-6 weeks 4
- 99% clinical cure or improvement rates comparable to ciprofloxacin, trimethoprim-sulfamethoxazole, and nitrofurantoin 4
Multidrug-Resistant E. coli
Fosfomycin demonstrates exceptional activity against MDR strains, which is particularly relevant given rising resistance patterns:
- 96.8% susceptibility among ESBL-producing E. coli isolates (1,604/1,657 isolates tested) 5
- 93.8% clinical effectiveness (75/80 patients) for complicated and uncomplicated UTIs caused by ESBL-producing E. coli 5
- In female adolescents with MDR E. coli UTIs: 97% clinical cure (68/70) and 94% microbiological cure (66/70) with single-dose therapy 3
- 96% overall susceptibility across 13 countries, with no significant difference between high-income and lower-middle-income settings 6
Guideline Recommendations
The 2024 European Association of Urology guidelines list fosfomycin trometamol 3g single dose as first-line treatment for uncomplicated cystitis in women 1. The 2024 JAMA consensus guidelines note that while oral fosfomycin lacks strong data for pyelonephritis, it is appropriate for lower UTI treatment 7.
Important Clinical Caveats
When NOT to Use Fosfomycin
- Pyelonephritis or perinephric abscess: Fosfomycin is NOT indicated for upper tract infections 2
- Men with UTI: Guidelines recommend 7-day courses of other agents (trimethoprim-sulfamethoxazole or fluoroquinolones) rather than single-dose fosfomycin 1
- Treatment failures: If bacteriuria persists or reappears after fosfomycin, select alternative agents 2
Species-Specific Considerations
While E. coli shows excellent susceptibility (86-96%), Klebsiella pneumoniae demonstrates alarmingly high resistance (98% in recent studies) 8. If K. pneumoniae is suspected, avoid empirical fosfomycin and obtain culture-guided therapy.
Resistance Monitoring
Contemporary E. coli resistance rates remain low (9.5% in recent surveillance), but plasmid-mediated resistance genes (particularly fosA3) are emerging 9, 10. The fosA3 gene was detected in 33% of fosfomycin-resistant strains, highlighting the importance of antimicrobial stewardship 10.
Practical Prescribing
- Dose: Single 3-gram oral dose 1, 2
- Timing: Can be taken without regard to food, though absorption is slightly faster when fasting 2
- Tolerability: Excellent safety profile with only 3% experiencing mild, self-limited diarrhea 3
- Follow-up: Routine post-treatment cultures are unnecessary in asymptomatic patients 1
- Relapse rate: Only 3% in clinical studies 3
Drug Interactions
Avoid co-administration with metoclopramide, which lowers serum concentrations and urinary excretion of fosfomycin 2. Cimetidine does not affect fosfomycin pharmacokinetics 2.
The evidence strongly supports fosfomycin as a highly effective, well-tolerated first-line option for E. coli cystitis in women, with particular value against multidrug-resistant strains where other oral options are limited.